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Weinvestigated the influence of an antiparasitic drug, levamisole
(2,3,5,6 - tetrahydro - 6- phenyl-imidazo (2,1 - b) thiazole -
hydrochloride) with potent immunomodulatory properties on the
course and development of experimental autoimmune encepha-
lomyelitis (EAE). EAEwas induced in femaleDarkAgouti (DA)ratsaged
two months by immunization with guinea pig spinal cord in complete
Freunds adjuvant. Following immunization animals were
subcutaneously treated everyother day with 2.2 mg/kg levamisole. The
course, development and characteristics of this autoimmune process
were monitored as indirect indicators of immune system activity.
Our results indicate that in EAE levamisole exerts
immunosuppressive effects when administered every other day from
the moment of immunization until the end of the disease. This
application regime and dose postponed the onset of the first clinical
signs, shortened the duration of the disease, abrogated the severity of
clinical symptoms and accelerated the recovery of sick animals. In the
period of induction and during EAE, levamisole also decreased the
severity of changes in the cerebral perivascular spaces. In the
peripheral blood of levamisole treated animals witb induced EAE, a
significant increase of CD4-CDB+ T cells was demonstrated.
Furthermore, all rats with induced EAE had decreased numbers of
CD4+CDB- T cells in their blood. These changes were in correlation
with clinical signs of EAE.
Key words: Dark Agouti rats, EAE, immunomodulation,
levamisole
INTRODUCTION
For these studies we utilized DA rats, a strain which has previously been
shown to be susceptible to clinical EAEfollowing MBP-CFAimmunization (Gasser
et al. 1973, Stepaniak et al. 1995). As an autoimmune disease of the central
nervous system induced by immunization with antigens of the nervous tissue,
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EAE has been widely explored as a model for multiple sclerosis (MS) in humans.
It was postulated that MS could be an autoimmune disorder but exact
mechanisms of disease onset and tissue damage are still not well understood
(Calder et al. 1989). However, one of the main characteristics of MS is a
demyelinisation process which is not present in acute EAE. This form of EAE is
characterized by spontaneous recovery of sick animals due to the exhaustion of
self reactive T-cell clones. On the contrary, a.nother form of the disease - chronic
EAE, is characterized by massive demyelinization and can be induced by
cyclosporine A treatment or immunization with nonstandard encephalitogens (i.e.
myelin oligodendrocyte glycoprotein - MOG)(McCombe et al. 1994). This form of
EAE probably resemble MS more closely (Sercarz et al. 1993) and because both
MS and EAE involve basic immunological mechanisms the latter has been Widely
explored.
Levamisole is well known as a potent anthelmintic drug effective against
Haemonchus spp., Trichostrongylus spp., Ostertagia spp., Cooperia spp.,
Nematodirus spp, Bunostomum spp., Oesophagostomum spp and Chabertia spp.
It is recommended especially for rumina.nts but has some side effects in other
species (Brander et al. 1994, Adams, 1995,Yolande 1996). Surprisingly, this drug
was discovered to exert numerous immunomodulatory effects as well. There is
voluminous literature concerning the immunomodulatory effects of levamisole
and it was concluded that its main effect is immunostimulation in patients with
suppressed immune system activity (Amery and Brynseels, 1992). Renoux and
Renoux (1972) reported the first experimental data concerning levamisole action
on components of the immune system. This topic is reviewed in detail elsewhere
(Symoens and Rosenthal 1976, Amery and Brynseels, 1992, Goodman et al.
i 995). The nature of levamisole action upon cells and molecules of the immune
system has been intensively investigated. It was documented that levamisole
induces synthesis of substances similar to thymic hormones (Renoux et al. 1980,
Hadden 1987, Amery and Brynseels, 1992). One possible way of levamisole
action could be regulation of the intracellular cGMP/cAMP ratio (Anderson et al.
1976, Hadden, 1977). According to the third theory, levamisole downregulates
the synthesis of natural immunosuppressive factors, thus enhancing the immune
response Schnaper et al., Lau et al. 1990). One of the target cells for levamisole
is the macrophage and it was reported that macrophage IL-1 secretion is
augmented in the presence of this drug (Kimball, 1993).
There is not much evidence about the influence of levamisole on EAE. The
first data originate from Spreafico et al. (1975) who demonstrated that in Lewis
rats, levamisole (3 mg/kg) applied in the first four days postimmunization
increased the incidence of the disease and severity of the symptoms. In another
study, Ryskova et al. (1988) showed that levamisole (20 mg/kg) and etimisole (15
mg/kg) if applied every day after immunization abrogate clinical signs and
histopathological brain lesions in guinea pigs with induced EAE.In the same study
it was also documented that etimisole decreased anti MBP-antibody (Myelin Basic
Protein) production while levamisole did not.
It is well known that in some clinical cases the ratio of CD4+CD8-/
CD4-CD8+ cells can be one of the indicators of immune system activity. An
elevated number of CD4+CD8- cells indicates enhanced activity while elevation
of CD4-CD8+ cells is a sign of decreased immune system activity (Tizzard, 1996).
It is also well documented that EAE develops as a consequence of CD4+CD8-
c~1I sensibilization with MBP (Holda and Swanberg, 1982, Burns at al., 1984,
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Saoudi et al. 1996) and that Th1 cells are probably of major significance. The role
of Th2 cells is not yet clearly established (Katz et al., 1995). Hauser et al. (1984)
proved that one of the consequences of EAE in mice was decreased CD4+CD8-
cell number in the peripheral blood of immunized animals. Fallis et al. (1987)
reported that in the venous blood of Lewis rats, the number of both investigated
T cell subpopulations (CD4+CD8- and CD4-CD8+) decreased even before the
onset of the first clinical signs of EAE. During the recovery period the number of
T cells increased. It was also postulated (Sedgwick, 1988) that CD4-CD8+ T cells
are not of greater importance for EAE induction because in CD4-CD8+ depleted
rats reinduction of EAE is not possible which is the same as in animals with
functional CD4-CD8+ lymphocytes. Furthermore, it is not clear if during the
recovery phase of EAE,the number of CD4-CD8+ cells in brain increases or their
activity is suppressed. Zeine and Owens (1993) demonstrated that during the
recovery period CD4-CD8+ T cells withdraw from the CNS. Vukmanovic et al.
(1990) reported that in DA rats with induced EAE the number of CD4-CD8+ was
slightly decreased in peripheral blood but significantly increased during the
recovery period.
The aim of this study was to investigate the influence of levamisole treatment
on the course, duration, clinical signs and severity of EAEsymptoms in female DA
rats. We also investigated histopathological changes in the brain of experimental
animals and the distribution of CD4-CD8+ and CD4+CD8- T cells in the
peripheral blood. The influence of levamisole on the immune system is of
particular interest for veterinary medicine because of its widespread use as an
anthelmintic drug.
MATERIAL AND METHODS
Animals. Inbred Dark Agouti (DA) female rats aged 2-3 months from a
breeding colony of the Medical Military Academy, Belgrade, were used for the
experiments. The animals were age-matched and housed at 4-5 per cage. They
were given a standard diet and tap water ad libitum.
Induction of EAE. EAEwas induced in DAfemale rats by intradermal injection
in the hind footpad of 0.1 ml of an emulsion containing guinea pig spinal cord
(GPSC) homogenate (20 mg/rat) in an equal volume of complete Freunds
adjuvant (CFA). CFA was made up with 8.5 parts of paraffin oil (Bayol F), 1.5 parts
of an emulgant (Arlacel A) and 6 mg/ml of heat-killed Mycobacterium
tUberculosis/ra~. In addition, the ratswere injected with 0.3 ml Bordetella penussis
vaccine (9 x 10 microorganisms/rat) in the dorsum of the same foot (Levine and
Wenk, 1965). Animals were scored daily for clinical signs of the disease on ascale
from 0 to 4 defined as follows: 0 - no clinical signs, 1 - flaccid tail, 2 - weakness of
hind limbs, 3 - paralysis of hind limbs and 4 - quadriplegia and moribund state
(Levine and Wenk 1965). Aggregate clinical scores represent the sum of clinical
signs for each day when the animal was paralyzed.
Levamisole treatment and experimental design. Our experiments were
conducted in two separate trials. In the first trial all immunized animals (n = 40)
were divided in two uniform groups. Animals from the EL group received SC
injections of 2.2 mg/kg levamisole hydrochloride in 0.5 ml aqueous solution every
other day starting from the day of immunization. Following immunization, the
control group of animals (E) was administered the same volume of sterile saline
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solution every other day. During this trial we monitored the onset of clinical signs,
course of the disease and severity of symptoms. All animals were sacrificed under
ether anesthesia and sections of the brain tissue were examined for the presence
of perivascular infiltrates. In the second trial, 32 animals were immunized in the
same way. Half of them were levamisole treated (group EL) while the other half
represented a positive control group (E). Furthermore, 4 additional negative
control groups consisting of 16 DA rats each were included. They consisted of
animals immunized only with CFA, some of which received saline solution (group
A, n=16), and some levamisole every other day (group AL, n = 16). The third and
fourth group (L and C) consisted of 16 animals each, that were not immunized at
all but were treated with levamisole or saline respectively. Half of these animals
were sacrificed at the moment of the maximal clinical score in groups E and EL
(day 14) and at the end ofthe recovery phase (day 21). The venous blood of these
animals was examined for the presence of T cell subpopulations CD4-CD8+ and
CD4+CD8- on days 14 and 21.
Histopathological evaluation of EAE. Animals were sacrificed 14 or 21 days
postimmunization and their brains processed for staining with haematoxylin and
eosin. Semithin (6 11m) serial sections of the brain were examined by light
microscopy for the presence of histopathological lesions characteristic of EAE. A
minimum of 12 sections per animal was examined and judged on a 0 - 4 scale as
follows: 0 - no lesions, 1- small meningeal infiltrates and solitary perivascular
infiltrates (lesions), 2 - meningeal infiltrates and small parenchymal lesions, 3 -
multiple perivascular lesions and 4 - marked, confluent lesions with necrotic
changes of brain parenchyma.
Expression of CD4 and CDB molecules on the lymphocytes. Heparinized
blood samples (25 UI/ml Heparin, ICN, Yugoslavia) were obtained by cardiac
puncture from rats under ether anesthesia. Blood was diluted (1 :1) by 0.1 M PBS
containing 0.02% NaN3, (pH=7.3) and layered on Ficol-Paque PLUS 1.077
gradient (Pharmacia, Biotech) prior to centrifugation (1200 rpm, 20 min.). The
bUffy ring was than collected and mononuclear cells washed 3 times in the same
buffer (1200 rpm, 5 min, +4 0C). Following the last centrifugation the supernatant
was discarded and cells resuspended in the same buffer supplemented with 2%
FCS and 5% normal rat serum. The number ofviabie cells was estimated by trypan
blue exclusion and counted in a Neubauer hemocfometer. Suspensions were
then adjusted with the same PBS buffer to 1.5 X 10 celis/rnl.
The number of CD4+ T cells was estimated by flow cytometry following
direct unicolour labeling of CD4 molecules with mouse anti-rat CD4 - FITC
monoclonal antibodies (clone W3/25, Serotec, MCA55F) of IgG1 isotype (10
Ill/sample in 1:50 dilution with PBS plus 0,1 NaN3). For isotype control of these
antibodies mouse IgG1-FITC (Mouse IgG1-FITC, Serotec, MCA 1209F) was used.
The number of CD8 molecules was estimated by indirect unicoiour
immunofluorescent labeling. As primary antibodies mouse anti-rat CD8 (clone
MRC OX-8, Serotec, MCA48G) IgG1 isotype (10 Ill/sample, previously diluted by
PBS containing 0.1 % NaN3 and 5% normal rat serum were used. Fluorescence
labeling was performed in the second step by 10 l;(1 of FITC - conjugated sheep
anti-mouse anti- IgG serum (INEP, Zemun). This antiserum was diluted 1:20 in
PBS containing 0.1% NaN3 and 5% normal rat serum. In order to exclude
nonspecific interactions of primary and secondary antibodies with components
ofthe system four control samples were introduced. They were as follows: isotype
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control - cells incubated with mouse IgG1-FITC (Serotec, MCA 1209F), cells
incubated with only primary antibodies, cells incubated with only secondary
antibodies and finally cells incubated with secondary antibodies and mouse
IgG1-FITC (Serotec, MCA 1209F). All samples were processed on the same day
by flow cytometry (FACScan; Becton Dickinson) using the Consort 30 program.
Details of the FACS analyses are described elsewhere (Melamed et al. 1979).
Data Analysis. All results are expressed as mean value (X) ± standard
deviation (SD). Data were analyzed by means of one-way analysis of variance
(ANOVA) and Student's t-test.
RESULTS
Trial I: Clinical data for EAE in the female DA rats immunized with GPSC (E)
and treated with 2.2 mgjkg levamisole every other day (EL) are presented in
Tables 1 and 2. The results showed that EAEwas induced in all animals (incidence
100%) but the severity of the symptoms differed significantly between levamisole
treated and the control group. In the levamisole treated group (EL) only two
animals showed signs of quadriplegia while in the control group 9 animals exibited
the most serious clinical stage (Table 1). Levamisole treatment significantly
postponed the onset of the clinical signs, shortened the duration of the.disease
and decreased the aggregate clinical score in sick animals. Moreover, in this
group of DA rats, the mean clinical score was decreased and the peak day was
delayed (Table 2).
Table1. EAE incidence and clinical signs in control (E) and levamisole treated








Numberof animals with clinical signs
o + ++ +++ ++++
o 1 1 9 9





Table 2. EAE parameters in control (E) and levamisole treated female DA
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Examination of the haematoxylin-eosin stained brain sections from the
animals included in this trial revealed the inhibitory effect of levamisole on the
development of brain lesions. In the levamisole treated group, brain lesions were
documented only in 40% of the animals. In this group of animals lesions were less
severe and these differences were statistically significant (Table 3).
Table 3. Perivascular mononuclear infiltrates in control (E) and levamisole treated female
DA rats (EL) following immunization with GPSC in complete Freunds adjuvant
Animals with Number of animals and severity
X±SD
Group n brain lesions of brain lesions
(%) 0 2 3 4
E 10 100 1 4 3 1 90
EL 10 100 6 2 1 0 80-
The course of the disease in the levamisole treated and control groups of
DA female rats with induced EAE is presented in Figure 1. It is evident that from
the day of onset, the mean clinical score was always lower in the levamisole treated
group. Furthermore, the peak day (when maximal clinical symptoms were
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Figure 1. Mean clinical score of EAE inthe levamisole treated (LE) group (n=20) and control (E) group
(n=20)
Figure 2. shows typical, well developed, brain lesions in DA rats with induced
EAE characterized by massive perivascular mononuclear infiltrates and signs of
necrosis.
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Figure 2. Massive perivascular mononuclear infiltrates and signs of necrosis in the brain sections of
DA female rats with induced EAE (+ + + +), HE, 400 X
Tria/II: In the second trial, the same characteristics of EAE in the levamisole
treated and control group were observed (data not shown here). In order to
estimate the influence of all substances used in EAE induction on the number of
CD4+CD8- and CD4-CD8+ cells, four additional groups were included (A, L, AL
and C) as described in the Material and methods section. Half of the animals were
sacrificed on day 14, when maximal clinical signs were expressed, while the other
half was sacrificed one week later during the remission phase.
The number (%) of T cells in the peripheral blood of all animals obtained by
FACS analyses, on day 14, is presented in Figure 3. In all negative control groups
%








A c E EL
Figure 3. Mean values for relative numbers (%)of CD4+CD8- and CD4-CD8+ T cells in the peripheral
blood of female DA rats on day 14 postimmunization
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(animals nonimmunized with encephalitogen - A, L, AL and C) the relative number
of CD4+CD8- T cells did not differ significantly. However, in groups E and EL,
their level was significantly lower. The decrease of the CD4+CD8- cells was more
marked in the EL group. Between the negative control groups, the number of
CD4-CD8+ did not differ either but the relative number of these cells was
significantly increased in groups E and EL. Again, the changes were more
expressed in the levamisole treated animals (EL group).
The number (%) of T cells in the peripheral blood of all animals on day 21
is presented in Figure 4. As on day 14, in all negative control groups (A, L, AL and
C) the relative number of CD4+CD8- T cells was similar but significantly decreased
in groups E and EL, even more than on the day 14. The relative number of
CD4-CD8+ did not differ between the negative control groups and group E either.











Figure 4. Mean values for relative numbers (%) of CD4+CD8- and CD4-CD8+ T cells in the peripheral
blood of female DA rats on day 21 postimmunization
DISCUSSION
Various inbred strains of rats differ in their susceptibility to encephalitogens
and in the DA strain it is possible to induce EAE by a single heterologous or
homologous nervous tissue injection with an adjuvant. Our results concerning
EAE characteristics, correlate with the findings of Vukmanovi6 et a/. (1990) and
Arsov et al (1995) who demonstrated a similar course and duration of the disease
in DA rats. In our study, the levamisole treated group of rats also developed acute
EAE but parameters of the disease were significantly different. Levamisole
treatment postponed the onset of the clinical symptoms, shortened the duration
of the disease and decreased the aggregate clinical score in sick animals. In this
group of DA rats, the mean clinical score was decreased and the peak day was
delayed (Table 2). These results are in agreement with findings of Ryskova et a/.
(1988) who reported suppressive effects of levamisole applied in the phase of
induction on EAE development in guinea pigs. The same authors demonstrated
decreased morbidity and mortality rates as well as a decreased late
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hypersensitivity reaction to MBP. However, in our experiments the mortality rate
wa.s small (data not shown) because the dose of the levamisole used was much
lower (2.2 vs. 20 mg/kg). In addition, another group of authors (Hierholzer and
Kuwert, 1975) noted the abrogating influence of levamisole on EAE course and
development. Interestingly, the first results about the influence of levamisole on
EAE (Spreafico et al. 1975) indicated potentiating effects of this drug if applied in
a dose similar to ours (3 mglkg).
Ryskova et al. (1988) reported that levamisole treatment of guinea pigs with
induced EAE decreased the severity of the brain lesions and similar findings were
obtained in our experiments. Moreover, clinical signs of EAE in our study,
correlated well with the degree of histopathological brain lesions. There is
particular disagreement in the literature concerning this problem and some
authors stated that histopathological changes (perivascular mononuclear cell
infiltrates) in the brains of rats with induced EAE do not always correspond to the
clinical signs of the disease (Krenger et al. 1986, Perry and Gordon, 1988).
In our second trial, it was documented that in the peripheral blood of DA
female ratswith induced EAE,the number of CD4+CD8- was significantly reduced
in both levamisole treated and non-treated groups in comparison to the values
obtained for the nonimmunized animals. Neither adjuvant nor levamisole alone
nor their combination altered the number of CD4+ CD8- cells. As previously stated
nearly the same values were obtained on days 14 and 21. On the contrary, the
number of CD4-CD8+ T cells was significantly increased in immunized animals
(except for group E on day 21) and especially in the levamisole treated group.
Our findings are in agreement with the results of Vukrnanovic et al. (1990) who
also documented that in EAE, the balance between lymphocyte subpopulations
is altered. The same authors found an increased number of CD4-CD8+ cells in
the peripheral blood during the period of recovery. Our results confirm this finding
and, in addition, we observed an even higher increase in the levamisole treated
group. Decrease of the CD4+CD8- T cell population in the peripheral blood could
be ascribed to increased migration into the target tissue (Hauser et al. 1984). The
results of Fallis et al. (1987) confirm that even before the EAE manifestation in
Lewis rats the number of both CD4-CD8+ and CD4+CD8- T cells was decreased
in the peripheral blood. In our experiments, a decrease of CD4-CD8+ cells was
not found on days 14 and 21 . Zeine and Owens (1993) demonstrated that during
the period of recovery the number of CD4+CD8- cells decreased in nervous
tissue. There is clinical evidence that levamisole applied to patients with multiple
sclerosis can normalize the CD4+/CD8+ index (Sun et al. 1994).
The immunosuppressive effect of levamisole in acute EAEwas a consistent
finding in our experiments and there are several mechanisms that might be
operative. Sampson and Lui (1976) stated that, apart from its stimulatory role,
levamisole can enhance activity of T cis cells. Another possibility is conected to
the role of histamine in EAE, because increased release of this mediator in the
CNS potentates EAE symptoms (Stanley et al. 1990), while levamisole can
neutralize histamine effects (De Cock et al. 1978). It was also documented that
pentoxifilline can exert protective effects in an EAE model (Nataf et al. 1993) by
changing the cAMP/cGMP balance in cells, thus blocking TNF - synthesis. This
effect was also ascribed to levamisole (Hadden, 1977). Recently, it was
emphasized that levarnisole contributes to the regulation of the immune system
by stimulating depressed functions and also by suppressing enhanced activity.
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The effects of levamisole are often compared to thymic peptides because of its
ability to correct an impaired CD4+/CD8+ index (Sibirjak et al. 1999).
REFERENCES
1. Adams RH, 1995. Veterinary Pharmacology and Therapeutics. VII Edition. The Iowa State University
Press, Ames.
2. Amery KP, Bruynsee/s JP, 1992, Levamisole, the story and the lessons, Int J Immunopharmacol, 14,
3,481-486.
3. Anderson R, Glover A, Koomnot HJ, Rabson AR, 1976, In vitro stimulation of neutrophil motility by
levamisole: maintenance of cGMP levels in chemotactically stimulated levamisole treated
neutrophils, J Immunol, 117, 428.
4. Arsov I, Pravica V, Badovinac V, Mostarica M, Lukic M, 1995, Selection for the susceptibility to
experimental allergic encephalomyelitis also selects for high IFN - production, Transpl Proc,
27, 1537-8.
5. Brander GC, Pugh OM, Bywater RJ, Jenkins WL 1994, Veterinary Applied Pharmacology and
Therapeutics, Bailliere Tindall. London.
6. Burns J, Rosenweig A, Zweiman B, Moskovitz A, Lisak R, 1984, Recovery of myelin basic protein
reactive T cells from the spinal cord of Lewis rats with autoimmune encephalomyelitis, J
Immunol, 132,2690-2,.
7. Calder V, Owen S, Watson C, Feldmann M, Davison A, 1989, MS: a localized immune disease of the
central nervous system, Immunol Tod. 10,3,99-103.
8. De Cock W, De Cree J, Verhaegen H, i 978, Restoration by levamisole of histamine inhibited E-rosette
formation of T-Iymphocytes of patients with allergies, Int Arch AI/erg Appllmmunol, 12, 19 - 24,
9. Fallis JR, Powers ML and Weiner LH, 1987, Serial analysis of peripheral blood T-cell phenotypes
and myelin basic protein reactivity in experimental allergic encephalomyelitis, Neurology, 37,
719-723,.
10. Gasser DL, Newlin CM, Palm J, Gonatas NK, 1973, Genetic control of susceptibility to experimental
allergic encephalomyelitis in rats, Science, 181,872-3.
11. Goodman V, Gili'!1{?-ns A, Ral/ TWR, Nies AS and Taylor P, 1995, The Pharmacology Basis of
Therapeutics 9 ed .. Pergamon. Press.
12. Hadden JW, 1977. Cyclic nucleotides in lymphocyte proliferation and differentiation; In
Immunopharmacology, Hadden, Coffey and Spreafico (Eds), 1-28 Plenum Medical Book Co.,
New York, London.
13. Hadden JW, 1987, Immunopharmacology of the immunotherapy of cancer, infection and
autoimmunity. Fundam Clin Pharmacal, t :4,283-96,.
14. Hauser S, Bahn K, Che M, Gilles F and Weiner L, 1984, Redistribution of Lyt-1 bearing T cells in
acute murine experimental allergic encephalomyelitis. Selective migration of Lyt-1 cells to the
central nervos system is associated with a transient depletion of Lyt-1 cells in peripheral blood.
J immunol, 133,3037-3042.
15. Hierholzer E, Kuwert E, 1975, Immunologische Wirksmkeit von Levamisol unter Verwendung des
Versuchmodells der experimentallen allergischen Encephalomyelitis (Immunoence-
phalomyelitis) am Kaninchen, Unpublished Report.
16. Holda J and Swanborg H, 1982, Autoimmune effector cells II. Transfer of experimental allergic
encephalomyelitis with a subset of T lymphocytes. Eur J immunol, 12, 453-455,.
17. KatzJD, BenoistC and Mathis 0, 1995,T helper cell subset in insulin-dependent diabetes, Science,
268, 185-188.
18. Kimball ES,1993, Experimental modulation of IL-1production and cell surface molecule expression
by levamisole. Ann N YAcad Sci. 23, 685, 259-68.
19. Krenger W, Honegger CG, Feurer C, Cammisuli S, 1986, Changes of neurotransmitter systems in
chronic relapsing experimental allergic encephalomyelitis in rat brain and spinal cord, J
Neurochem, 47, 1247-54.
20. Lau C, Stanojev 0, Visconti V, Pang H, Krepinsky G, Grey A, Wang E and Ishaque A, 1993,
Purification, characterisation and structural elucidation of the active moiety of the previously
called Suppressor Activating Factor (SAF). Cel/lmmunol, 125, 92-106.
21. Levine S, Wenk EJ, 1965, A hyperacute form of allergic encephalomyelitis, Am J Pathol, 47, 61-80.
22. Mc Combe PA , de Jersey J, Pender MP, 1994, Inflammatory cells, microglia and MHC class II
antigen-positive cells in the spinal cord of Lewis rats with acute and chronic relapsing
experimental autoimmune encephalomyelitis. J Neuroimmunol, 551: 2, 153-167.
23. Melamed M, MUI/aney P, Mendelsohn M, 1979, Flow oytometrv and Sorting, Willey & Sons, LTD,
New York
Acta Veterinaria (Beograd), Vol. 51. No. 2-3, 89-100, 2001.
lli6 V. et al. Levamisole modulates experimental autoimmune encephalomyelitis (EAE)
in DA rats
99
24. Nataf S, Louboutin JP, Chabannes 0, Feve JR, Muller JY, 1993, Pentoxifilline inhibits experimental
allergic encephalomyelitis, Acta Neurol Scand. 88,97-9.
25. Perry VN, Gordon S, 1988, Macrophages and microglia in the nervous system, Trends Neurosci,
11,273-77.
26. Ryskova 0, Zhitnuhin LY, Chizhnyak MG, 1988, Effects of levamisole and etimisole on the
development of experimental allergic encephalomyelitis. J Hig Epid Mic Immunol., 32, 1,
105-112.
27. Renoux G, Renouux M, 1972, Imunologie: action immunostimulante de derives du phenylimi-
dothiazole sur les cellules spleniques formatrices d'anticorps, Cr Acad Sci, Paris, 247, 756-7.
28. Renoux G, 1980, The general immunopharmacology of levamisole. Drugs 19: 89-99.
29. Sampson 0, Lui A, 1976, The effect of levamisole on cell mediated immunity and suppressor cell
function, Canc Res, 36, 952.
30. Saoudi A, Seddon B, Fowell 0, Mason 0, 1996, The thymus contains a high frequency of cells that
prevent autoimmune diabetes on transfer into prediabetic recipients. J Exp Med, 184, 2393-8.
31. Schnaper W, Pierce C, and Aune T, 1984, Identification and initial characterisation of concavalin-A
and interferon induced human suppressor factor: evidence for a human equivalent of murine
soluble immune response suppresor (SIRS). J Immunol, 132,2429-35.
32. Sedgwick OJ, 1988, Long-term depletion of CD8+ T cells in vivo in the rat: no observed role for
CD8+ (cytotoxic/suppressor) cells in the immunoregulation of experimental allergic
encephalomyelits. Eur J lmmunol, 18, 495-502.
33. Sercarz E.E., Lehman P.V., Amental A et ai, 1993: Dominance and crypticity of T cell antigenic
determinants. Ann Rev tmmunol, 11: 729-66.
34. Sibirjak SV,Sadikov RF, Magazov RS, Sergeeva SA, 1999, Immunomodulatori, Ud'benik UFA, GUP
Immunopreparat, 49-52.
35.Spreafico F, Vecchi A, MantovaniA, Poggi A, Franchi G, Anaclero A, Garattini S, 1975,
Characterization of the immunostimulants levamisole and tetramisole. Eur. J. Cancer, 11,
555-61.
36. Stanley NC, Jackson FL, Orr E, 1990, Attenuation of experimental autoimmune encephalomyelitis
by compound 48/80 in Lewis rats, J Neuroimmunol, 29, 223-8.
37. Stepaniak A, Gould KE, Sun 0, Swanborg RH, 1995, A comparative study of experimental
autoimmune encephalomyelitis in Lewis and DA rats. J Immunol, 155, 2762-69.
38. Sun A, Chaing CP, Chiou PS, Wang JT, Liu BY, Wu Ye, 1994, Immunomodulation by levamisole in
patients with aphtous ulcers or oral lichen planus, J Oral Pathol Med, 23, 172-7.
39. Symoens J, Rosenthal M, 1977, Levamisole in the modulation ofthe immune response: The current
experimental and clinical state. J Reticuloendothel Soc, 175-221.
40. Tizzard RI, 1996, Veterinary Immunology 5tn ed. WB Saunders Company, Philadelphia, London.
Toronto, Montreal, Sydney, Tokyo.
41. vukmsnovic S, Mostarica M, Zalud I, Ramie Z and Lukic M, 1990, Analysis of T cell subset after
induction of experimental autoimmune encephalomyelitis in susceptible and resistant strains
of rats. J Neuroimmunol, 27, 63-9.
42. Yolande MB, 1996, The Veterinary Formulary. Handbook of Medicines Used in Veterinary Practice.
Third Edition. Royal Pharmaceutical Society of Great Britain. London.
43. Zeine R and Owens T, 1993, Loss rather than downregulation of CD4+ T cells as a mechanism for
remission from experimental allergic encephalomyelitis. J Neuroimmunol, 44, 193-8.
MODULACIJA EKSPERIMENTALNOG AUTOIMUNOG ENCEFALOMIJELITISA (EAE) DA
PACOVA LEVAMIZOLOM
IUC V, LAZAREVIC M, RAUSKI ALEKSANDRA, POPOVIC N i KOSAC D
SADRZAJ
U ovom radu su prikazani rezultati ispitivanja anthelmintika levamizola
(2,3,5,6 tetrahidro - 6 - fenil - imidazo (2,1 - b) tiazol hidrohlorida) sa sna'nim
imunomodulatornim svojstvima na tok i razvoj eksperimentalnog autoimunog
encefalomijelitisa (EAE). EAE je indukovan imunizacijom zenki pacova soja DA
(Dark Agouti) starih dva meseca pomo6u homogenata kicrnene mo'dine
zamorceta u kompletnom Freundovom adjuvansu. Posle imunizacije, zivotinje su
100 Acta Veterinaria (Beograd), Vol. 51. No. 2-3, 89-100, 2001.
Ili6 V. et al. Levamisole modulates experimental autoimmune encephalomyelitis (EAE)
in DA rats
tretirane subkutanim injekcijama levamizola (2.2 mg/kg) svaki drugi dan a praceni
su tok, razvoj i karakteristike ovog autoimunog oboljenja kao indirektni indikatori
aktivnosti irnunoloskoq sistema. Postignuti rezultatiukazuju da levamizol ispoljava
imunosupresivno delovanje u modelu EAE ako se aplikuje svaki drugi dan od
momenta imunizacije do kraja bolesti. Primenjena doza i rezirn aplikacije odlo'ili
su momenat pojavljivanja prvih klinickih simptoma, skratili trajanje bolesti, ublaziii
ispoljavanje simptoma i ubrzali oporavak bolesnih zivotin]a. U periodu indukcije
i tokom EAE-a levamizol je smanjio stepen promena u cerebralnim
perivaskularnim prostorima. U venskoj krvi zenki pacova sa indukovanim EAE i
tretiranim levamizolom uoceno je znacajno pove6anje broja CD4-CD8+ T 6elija.
Osim toga, u obe imunizovane grupe zivotinja zapazeno je smanjenje broja
CD4+CD8- 6elija. ave promene su bile u skladu sa klinickorn slikom bolesti.
